Drugs / Empasiprubart
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07610564 | Jun 2026 → Feb 2028 expected | multifocal motor neuropathy | argenx | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07612020 | Mar 2026 → Mar 2027 expected | — | argenx | Recruiting | No outcome recorded |
| Phase 1 | NCT04532125 | Aug 2020 → Aug 2022 | — | argenx | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT07673627 | Jun 2026 → Oct 2027 expected | AChR+ myasthenia gravis, generalized myasthenia gravis | argenx | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07284420 | Dec 2025 → Mar 2028 expected | AChR+ myasthenia gravis, generalized myasthenia gravis | argenx | Recruiting | No outcome recorded |
| Phase 2 | NCT06284954 | Aug 2024 → Nov 2026 expected | dermatomyositis | argenx | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05907096 | Feb 2024 → Oct 2025 overdue | — | argenx | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05405361 | Jan 2023 → Sep 2029 expected | multifocal motor neuropathy | argenx | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05225675 | Mar 2022 → Jun 2024 | multifocal motor neuropathy | argenx | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07638566 | Sep 2026 → Apr 2028 expected | chronic inflammatory demyelinating polyradiculoneuropathy | argenx | Not yet recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07091630 | Sep 2025 → Oct 2027 expected | chronic inflammatory demyelinating polyradiculoneuropathy, polyneuropathy, inflammatory demyelinating, chronic | argenx | Recruiting | No outcome recorded |
| Phase 3 | NCT06920004 | Aug 2025 → Sep 2027 expected | polyneuropathy, inflammatory demyelinating, chronic | argenx | Recruiting | No outcome recorded |
| Phase 3 | NCT06742190 | Dec 2024 → Sep 2026 expected | multifocal motor neuropathy | argenx | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Empasiprubart | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07091630 ↗ |
| Known as | ARGX-117 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05405361 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5314673 ↗ |
| Route | Intravenous | “Subjects receiving ARGX-117 IV” NCT04532125 ↗ |